Table 1 Clinical data of the 8 patients.

From: Longitudinal MRI evaluation of the efficacy of non-enhanced lung cancer brain metastases

Case

Gender

Age

Site of lung cancer

Site of BM

Number of

BM

Annotation

Size of BM

Stage of lung cancer

Enhancement type

Treatment

Efficacy

evaluation

P1

Female

57

Inferior lobe of left lung

Left frontal lobe

1

0.6 × 0.6 cm

T1N2M1 IV

Mild enhanced → enhanced

Chemotherapy + targeted therapy + immunotherapy + radiotherapy

PR

P2

Male

69

Inferior lobe of left lung

Left cerebellum

1

0.5 × 0.6 cm

T4N3M1 IV

Non-enhanced

Chemotherapy + targeted therapy + radiotherapy

PD

P3

Female

59

Middle lobe of right lung

Right parietal lobe

1

0.8 × 0.9 cm

T2N0M1 IV

Non-enhanced

Chemotherapy + radiotherapy + immunotherapy

PD

P4

Male

47

Superior lobe of left lung

Right parietal lobe

1

1.6 × 1.7 cm

T1N2M1

Non-enhanced

Chemotherapy + + radiotherapy + targeted therapy

PD

P5

Male

73

Superior lobe of right lung

Left frontal lobe

1

Foci 1

2.2 × 2.8 cm

T2N0M1 IV

Obvious enhanced

Chemotherapy + targeted therapy + radiotherapy

PR

Left parietal lobe

1

Foci 2

0.6 × 0.9 cm

Non-enhanced

PD

P6

Female

54

Inferior lobe of left lung

Left frontal lobe

1

Foci 1

1.7 × 2.1 cm

T4N0M1 IV

Obvious enhanced

Chemotherapy + targeted therapy + radiotherapy

PR

Left thalamus

1

Foci 2

3.2 × 3.6 cm

Obvious enhanced→Non-enhanced

SD

P7

Male

33

Inferior lobe of right lung

Left temporal lobe

1

Foci 1

1.0 × 1.3 cm

T1N3M1 IV

Enhanced

Chemotherapy + immunotherapy + targeted therapy + radiotherapy

CR

Brainstem

1

Foci 2

0.6 × 0.7 cm

Non-enhanced

CR

P8

Male

71

Inferior lobe of left lung

Left temporal lobe

4

Foci 1

1.6 × 1.8 cm

T1bN2M1 IV

Enhanced

Chemotherapy + immunotherapy + targeted therapy + radiotherapy

CR

Right temporal lobe

1

Foci 2

1.7 × 1.7 cm

Non-enhanced

PR

  1. Foci 1 Enhanced BM; Foci 2 non-enhanced BM. CR: Complete Response; PR: Partial Response; SD: Stable Disease; PD: Progressive Disease.